Valuation models
price $30.52 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused40.60 – 84.6855.7245% undervaluedDCF · Perpetuity growth · 10y37.24 – 76.9550.8740% undervaluedDCF · EBITDA exit · 5y44.40 – 49.1446.7135% undervaluedDCF · EBITDA exit · 10y40.04 – 48.1743.9130% undervaluedP/E · peers26.81 – 54.5048.3837% undervaluedP/E · own history26.60 – 45.4938.0720% undervaluedPEG—53.7143% undervaluedEV/EBITDA · peers29.44 – 59.7137.3518% undervaluedEV/Revenue · peers46.65 – 80.9762.5851% undervaluedEarnings power value21.07 – 40.6228.477% overvaluedDividend discount30.54 – 94.1448.1137% undervaluedWall St. consensus target—30.50at targetCost of capital (WACC)—6.19%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
55.72
Pfizer closed at $30.52 — undervalued by 45% vs model.
40.60the model's range84.68
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
28.47 – 62.58
Wall St. target
30.50 0% above
Below model, 1y
20 of 31 days
How it is valued
Valued asMature & stable
Low/slowing growth (~3% recent)Moderate margins (12% net margin)Strong dividend yieldHighly cyclical earningsStrong FCF yield (5.2%)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.